Four things to know:
1. Mr. Slosman will replace outgoing CEO James Barry, PhD. He will also fill Dr. Barry’s seat on the company’s board of directors.
2. His goal is to expand the availability of the company’s CGuardTM Embolic Prevention System, designed for the prevention of stroke caused by carotid artery disease.
3. The CGuard system prevents peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining perfusion to the external carotid artery and branch vessels.
4. Mr. Slosman served in commercial leadership positions at Johnson & Johnson, GE Healthcare and Baxter, and is a former CEO of Ovalum.
More articles on devices:
3 orthopedic surgeons to expand services at new Iowa facility
2 recent value-based partnerships for orthopedic procedures
DePuy Synthes recalls devices used in spine fixation system: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.